title: Characterization of the hemodynamic activities of fenoldopam and its enantiomers in the dog.
abstract: Fenoldopam (SK&F 82526) is a potent and selective dopamine DA-1 agonist with demonstrated renal vasodilator and antihypertensive activities in experimental animals and humans. Fenoldopam is a racemic mixture of two enantiomers, SK&F R-82526 and SK&F S-82526. The R-enantiomer is uniformly reported to be more potent than the racemate; in contrast, there is controversy regarding potency of the S-enantiomer. In these studies, the renal and systemic hemodynamic activities of fenoldopam and its enantiomers are characterized in anesthetized, phenoxybenzamine-treated dogs. The results show that the renal and systemic vasodilator activities of fenoldopam are properties of the R-enantiomer; the S-enantiomer is essentially inactive. The renal and systemic vasodilator properties of SK&F R-82526 are antagonized in a competitive fashion by the DA-1 antagonist, SK&F R-83566, but not the DA-2 antagonist, domperidone. Ganglionic blockade did not attenuate renal vasodilation associated with SK&F R-82526. Thus, the mechanism of SK&F R-82526-associated vasodilation, like that previously established for fenoldopam, is via stimulation of postganglionic DA-1 receptors.
authors.affiliation: Department of Pharmacology, Smith Kline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406-0939.
authors.forename: L B
authors.initials: LB
authors.lastname: Kinter
authors.forename: E
authors.initials: E
authors.lastname: Horner
authors.forename: W A
authors.initials: WA
authors.lastname: Mann
authors.forename: J
authors.initials: J
authors.lastname: Weinstock
authors.forename: R R
authors.initials: RR
authors.lastname: Ruffolo
mesh_terms: D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001920:Bradykinin / Q000494:pharmacology; D004285:Dogs; D004294:Domperidone / Q000494:pharmacology; D004298:Dopamine / Q000494:pharmacology; D015259:Dopamine Agents / Q000494:pharmacology*; D005260:Female; D018818:Fenoldopam; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D018738:Hexamethonium; D006584:Hexamethonium Compounds / Q000494:pharmacology; D008297:Male; D012079:Renal Circulation / Q000187:drug effects; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D014655:Vascular Resistance / Q000187:drug effects; D014665:Vasodilator Agents / Q000494:pharmacology*
chemical_list: D015259:Dopamine Agents; D006584:Hexamethonium Compounds; D014665:Vasodilator Agents; D018738:Hexamethonium; D004294:Domperidone; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D018818:Fenoldopam; D001920:Bradykinin; D004298:Dopamine